Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence

Abstract

In clinical practice guideline-adherent secondary prevention drug therapy is linked with an improved 1-year survival. Comorbidities and no interventional treatment were strong negative predictors for guideline-adherent discharge medication.

Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007

“…But a larger contribution to mortality decrease came from drug treatment for secondary prevention after AMI. 27 Our study has several limitations. Most importantly, the use of multiple data sources of varying quality, especially data available on treatment uptakes, derived from national registries.…”

Effect of Beta Blockers and Renin–Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

“…8,9,31 Accordingly, the adherence to these guideline-based medications differs substantially among cardiovascular societies. 32,33 In South Korea, based on our nationwide data, BBs (59.8%) and ACEIs/ARBs (78.3%) were used far less often during the study period than other evidence-based medicines such as aspirin, adenosine diphosphate receptor antagonists, and statins. Particularly, as the number of PCIs for AMI increased, BB treatment decreased substantially over time, with only half of the patients treated in the 2012 to 2013 period receiving PCI.…”

Direct healthcare costs and resource consumption after acute coronary syndrome: a real-life analysis of an Italian subpopulation

“…[10][11][12] The following resource consumptions were evaluated: reimbursed drugs (source: public price reimbursed by the INHS for drugs distributed by pharmacies and real price to be paid by the INHS for drugs distributed via direct distribution or 'distribution on behalf'; reference years 2008-2009), diagnostic-therapeutic procedures and outpatients visits (source: national and regional tariffs), and hospitalizations and 1-day hospital stays (source: Regional Health Service (RHS) tariffs for the supply of hospital care for the years 2008 and 2009 13 ).…”